HighTide Therapeutics Inc (2511.HK)
HKD 1.8
(5.88%)
HKD 1.8
(5.88%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 18.09 Million CNY | -98.73% |
| 2022 | 1.42 Billion CNY | 15.02% |
| 2021 | 1.24 Billion CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | - CNY | 0.0% |
| 2024 Q1 | - CNY | -100.0% |
| 2023 Q3 | 3.5 Million CNY | -99.81% |
| 2023 Q2 | 1.86 Billion CNY | 8.08% |
| 2023 FY | 18.09 Million CNY | -98.73% |
| 2023 Q1 | 1.72 Billion CNY | 21.23% |
| 2023 Q4 | 18.09 Million CNY | 416.91% |
| 2022 Q4 | 1.42 Billion CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 52.86 Million HKD | 65.779% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.93 Billion HKD | 99.695% |